Orphan diseases Market information, by Type of Diseases (autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders), Type of Treatment (gene therapy, cell therapy, drug therapy , End user (hospital and clinics, research laboratory) -Global Forecast to 2027
ID: MRFR/Pharma/1907-HCR | February 2021 | Region: Global | 85 pages
Market Scenario:
Global orphan diseases market also known as rare disease is growing rapidly. It affects a very small percentage of the global population. Most of the orphan diseases are genetic and is remains throughout the life of the patient. There are no exact number of diseases available but approximately there are about 7000 different rare diseases and disorders throughout the globe. Global orphan diseases market is expected to grow at the average CAGR of 24.9% constantly throughout this period 2015-2022. It is also expected that this market which was US$ 121.6 billion in 2015 will grow to US$ 576.9 billion by 2022.However due to lack of awareness, correct diagnosis, correct treatments and availability of healthcare facilities are inhibiting the growth of the global orphan diseases market.
Study Objectives of Global Orphan Diseases Market:
- To provide detail analysis of the market structure along with forecast for the next 5 years about various segments and sub-segments of the global orphan diseases market.
- To provide insights about factors affecting the market growth.
- To analyze the global orphan diseases market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.
- To provide past and estimated future revenue of the market’s segments and sub segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific and Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future growth prospect.
- To provide country level analysis of the market for segments which includes by type and its sub segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments in the global orphan diseases market.
Orphan Diseases Market by Type of Treatment
Segments:
Global orphan diseases market has been segmented on the basis of types of diseases which includes autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders and others. On the basis of treatment type it segmented into gene therapy, cell therapy, drug therapy and others. On the basis of end user the market is segmented into hospital and clinics, research laboratory and others.
Regional Analysis of Global Orphan diseases Market:
Considering the global scenario of this market, North American region is believed to be the largest market of the global orphan diseases market. Moreover the European market is also growing and is the second largest market for global orphan diseases. On the other hand, Asia-Pacific’s orphan disease market is expected to grow at a significant rate during the forecasted period. Rest of the World is likely to have a limited but steady growth with respect to this market.
Key Players for Global Orphan diseases Market:
Some of the key players in this market are: Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Alexion (US), Sanofi (French), Vertex Pharmaceuticals Incorporated (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc (US), AbbVie Inc. (US)
The report of global orphan diseases market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.
Intended Audience
- Hospitals and clinics
- Orphan diseases drug manufacturers and suppliers
- Government and independent regulatory authorities
- Research and development (R&D) companies
- Market research and consulting service providers
- Medical research laboratories
- Potential investors
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size |
|
| CAGR | 24.9% (2015-2022) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type of Diseases, Type of Treatment, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Alexion (US), Sanofi (French), Vertex Pharmaceuticals Incorporated (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc (US), AbbVie Inc. (US) |
| Key Market Opportunities |
|
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The Global Orphan Diseases Market is projected grow at approximately 24.9% CAGR during the assessment period (2016-2023).
The valuation of the Global Orphan Diseases Market is estimated to increase to USD 576.9 BN by the end of 2023.
Spurting growth in the Healthcare sector and growing awareness among populaces are the major tailwinds pushing the growth of the Global Orphan Diseases Market.
North America holds the largest share in the Global Orphan Diseases Market, followed by Europe and the Asia Pacific, respectively.
Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), CELGENE CORPORATION (US), Pfizer Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Alexion (US), Vertex Pharmaceuticals Incorporated (US), Sanofi (French), GlaxoSmithKline plc. (UK), AbbVie Inc. (US), and Merck & Co., Inc. (US), are some of the major players operating in the Global Orphan Diseases Market.
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5 Market Factor Analysis
5.1 Value/Supply Chain Analysis
5.2 Porter's 5 Forces Analysis
5.3 Pricing Analysis
5.4 Investment Opportunity Analysis
5.5 Merger and Acquisition Landscape
6 Global Orphan diseases Market Market, By Disease Type (USD Million)
6.1 Introduction
6.2 Market Size By Disease Type
6.2.1 Autoimmune Disorders
6.2.2 Genetic Disorders
6.2.3 Blood Disorders
6.2.4 Cancer
6.2.5 Growth Disorder
6.2.6 Cardiovascular Diseases
6.2.7 Neurological Disorders
6.2.8 Respiratory Disorders
6.2.8 Digestive Disorders
6.2.9 Eye Disorders
6.2.10 Others
7 Global Chronic Disease Management Market, By Treatment Type (USD Million)
7.1 Introduction
7.2 Market Size By Treatment Type
7.2.1 Gene Therapy
7.2.2 Drug Therapy
7.2.3 Drug Therapy
7.2.4 Others
8 Global Chronic Disease Management Market, By End User (USD Million)
8.1 Introduction
8.2 Market Size By End User
8.2.1 Hospitals and Clinics
8.1.2 Research Laboratories
8.1.3 Others
9 Global Orphan Disease Market, By Region (USD Million)
9.1 Introduction
9.2 Market Size By Region
9.3 Market Size By Region
9.3.1 North America
9.3.1.1 The U.S.
9.3.1.2 Canada
9.3.2 Latin America
9.3.3 Europe
9.3.3.1 Western Europe
9.3.3.1.1 Germany
9.3.3.1.2 France
9.3.3.1.3 Italy
9.3.3.1.4 Spain
9.3.3.1.5 UK
9.3.3.2 Eastern Europe
9.3.4 Asia-Pacific
9.3.4.1 Asia
9.3.4.1.1 Japan
9.3.4.1.2 China
9.3.4.1.3 India
9.3.4.1.4 Australia
9.3.4.1.5 Republic of Korea
9.3.4.2 Rest of Asia-Pacific
9.3.5 Middle East & Africa
10 Company Landscape
10.1 Introduction: Key Players
10.2 Market Share Analysis
10.3 Key Development & Strategies
11 Company Profiles
11.1 Bristol-Myers Squibb Company
11.1.1 Company Overview
11.1.2 Product/Business Segment Overview
11.1.3 Financials
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 Novartis AG
11.2.1 Overview
11.2.2 Product/Business Segment Overview
11.2.3 Financials
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 CELGENE CORPORATION
11.3.1 Overview
11.3.2 Product/Business Segment Overview
11.3.3 Financials
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.4 F. Hoffmann-La Roche Ltd
11.4.1 Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financials
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.5 Pfizer Inc.
11.5.1 Overview
11.5.2 Product/Business Segment Overview
11.5.3 Financials
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Alexion
11.6.1 Overview
11.6.2 Product/Business Segment Overview
11.6.3 Financials
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Sanofi
11.7.1 Overview
11.7.2 Product/Business Segment Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Vertex Pharmaceuticals Incorporated
11.8.1 Overview
11.8.2 Product/Business Segment Overview
11.8.3 Financials
118.4 Key Developments
11.8.5 SWOT Analysis
11.9 GlaxoSmithKline plc.
11.9.1 Overview
11.9.2 Product/Business Segment Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Merck & Co., Inc
11.10.1 Overview
11.10.2 Product/Business Segment Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 AbbVie Inc.
11.11.1 Overview
11.11.2 Product/Business Segment Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
List of Tables
TABLE 1 GLOBAL ORPHAN DISEASE MARKET, 2020-2027 (USD MILLION)
TABLE 2 GLOBAL ORPHAN DISEASE MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY TRATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE
FIGURE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY TREATMENT TYPE
FIGURE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER
FIGURE 6 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION
FIGURE 7 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)